We have shown previously that overexpression of the e isoform of protein kinase C (PKCe) in rat colonic epithelial cells causes malignant transformation, possibly by interacting with the ras signal transduction pathway (Oncogene 12: 847, 1996). We have now performed experiments to examine certain early steps in the ras signaling pathway. A marked increase of Raf-1 phosphorylation was detected in tumorigenic ras-transformed D/ras as well as in D/e cells (overexpressing PKCe), compared to the nontumorigenic D/WT parental line. Moreover, in the PKCe-transformed D/e cell line, stable transfection with a dominant-negative raf-1 (DNraf) sequence caused complete regression of the neoplastic phenotype. These results suggested that PKCe-induced transformation was associated with increased Raf-1 activation, and that DNraf could block the oncogenic eect of PKCe. Furthermore, transfection of D/WT cells with dominant-negative ras induced arrest of cell growth, and subsequent transfection with PKCe cDNA enhanced cell proliferation and induced neoplastic transformation. These results suggest that ras acts upstream of PKCe, and that overexpression of PKCe circumvents the block in cell proliferation caused by dominant-negative ras. We conclude that PKCe exerts its oncogenic activity in rat colonic cells by aecting the ras signaling cascade at the level of Raf-1 activation.
We have demonstrated that the epsilon isoform of protein kinase C (PKCe) is oncogenic when overexpressed in rat colonic epithelial cells . In the previous report, we analysed the expression of several PKC isoforms in a nontumorigenic rat colonic epithelial cell line FRC/TEX CLD (D/WT), and in a derivative tumorigenic Ha-rastransformed FRC/TEX CLD/H-ras line (D/ras) (Pories et al., 1993) . PKCe was markedly increased in D/ras cells when compared to the non-neoplastic D/ WT line. To assess whether overexpression of PKCe was involved in the transformed phenotype, we stably transfected D/WT cells with a PKCe cDNA construct. Overexpression of PKCe induced complete in vitro and in vivo neoplastic transformation.
Because PKCe expression was found to be altered in D/ras cells, our ®ndings suggested that PKCe might exert its oncogenic activity by interacting with the ras signal transduction pathway. In particular, although it has been shown that p21ras can recruit Raf-1 kinase to the plasma membrane, this interaction is not sucient for complete Raf-1 activation, which occurs via phosphorylation of speci®c serine residues by a Raf kinase-kinase (Daum et al., 1994) . Several reports have suggested that PKCe and PKCa are likely candidates for this kinase in mammalian cells (reviewed in: Perletti and Monti, 1996; Daum et al., 1994; Malarkey et al., 1995) . We, therefore, focused new experiments on the role of PKCe in ras signal transduction, at the level of Raf-1 activation.
Based on the ®ndings described above, we hypothesize that PKCe interacts with the ras signaling pathway, likely by activating Raf-1.
Raf-1 phosphorylation is increased in D/ras and D/e cells in comparison with D/WT cells
We analysed the extent of Raf-1 protein expression and phosphorylation in D/WT, D/ras and D/e cells. To examine Raf-1 protein expression, cells were serumstarved for 28 h and incubated for 10 min with serumcontaining medium. Cells were subsequently lysed and equal amounts of protein for each cell line were analysed by SDS ± PAGE, blotted onto nitrocellulose and probed with an anti-Raf antiserum as previously described . To determine Raf-1 phosphorylation, after a 24 h period of serum starvation, cells were labeled with 32 P and incubated at 378C for 4 h. At the end of this period, cells were incubated for 10 min with serum-containing medium and subsequently lysed, immunoprecipitated with Protein A-Sepharose-conjugated anti-Raf-1, and analysed by SDS ± PAGE (Blind et al., 1995) . The results in Figure 1a show that both D/ras and D/e cells contained only slightly higher (&1.5-and &1.3-fold, respectively, by densitometry) Raf-1 protein immunoreactivity compared to D/WT cells. However, despite similar levels of Raf-1 protein expression, Raf-1 phosphorylation was markedly enhanced in D/ras (&ninefold) and D/e cells (&sixfold), as compared to D/WT cells (Figure 1b) .
These ®ndings suggest that PKCe may directly or indirectly induce an increase of Raf-1 phosphorylation, and that this eect is unrelated to the level of Raf-1 expression. We favor a direct eect, because Raf-1 has been shown to be phosphorylated by PKCe in COS cells (Cai et al., 1997) . Because Raf-1 phosphorylation is an index of its activation status, our data support the hypothesis that PKCe is involved in Raf-1 activation.
Dominant-negative raf-1 reverses transformation in D/e cells
We stably transfected D/e cells with a catalytically inactive, dominant-negative raf (DNraf). The dominant-acting mutated form of Raf-1 cDNA was obtained by site-directed mutagenesis of the ATP binding domain (described in Cacace et al., 1996) . The gene was cloned into the pBABE expression vector containing an SV40-driven puromycin resistance gene, and The growth parameters of each cell line are summarized in Table 1 . Compared to D/e cells, D/e/ DNraf cells displayed a signi®cant impairment of both growth rate and saturation density. In vitro transformation characteristics were signi®cantly altered in D/e/ DNraf cells; transformed foci were absent in this cell line, which was unable to grow and generate colonies in soft agar. Thus, D/e cells transfected with DNraf expressed the growth characteristics displayed by the parental, nontumorigenic D/WT line.
Furthermore, D/e/DNraf cells showed a highly attenuated in vivo tumorigenic pro®le; whereas D/e cells induced large palpable tumors (average size measured 30 days post-injection was 80 mm) which were detectable at day 14, no tumors were generated 30 days after subcutaneous injection of 10 6 D/e/DNraf cells (Table 1) . Because DNraf inhibited the transformed phenotype induced by PKCe overexpression in D/WT cells, PKCe appears to exert its oncogenic eect by acting upstream of Raf-1 kinase.
PKCe reverses the inhibition of cell growth caused by dominant-negative ras
We stably transfected D/WT cells with a ras N17 dominant-negative sequence (Feig and Cooper, 1988) cloned into the pBABE vector. In these D/N17 cells, ras N17 caused growth arrest after exposure to 0.5 mg/ ml puromycin for 12 days. By microscopic observation, cells expressing ras N17 underwent 3 ± 4 division cycles and then stopped proliferating. At this stage, the eect of dominant-negative ras on cell morphology was remarkable; D/N17 cells were scattered and verȳ attened and enlarged, resembling giant cells ( Figure  2d ). Virtually all transfected cells displayed this morphology and were able to survive in culture up to 15 days after growth arrest. These eects on growth and morphology were not observed when D/WT cells were transfected with an empty pBABE vector, nor Subsequently, cells were incubated for 10 minutes in serumcontaining medium. At the end of this period, whole cell lysates from the three cells lines were electrophoresed, transferred onto nitrocellulose and probed with an anti-Raf-1 antiserum as previously described . (b), Phosphorylation of immunoprecipitated Raf-1 in D/WT, D/ras and D/e cells. After a 24 h serum starvation period, cells were labeled with 32 P and incubated at 378C for 4 h. At the end of this preincubation, cells were treated for 10 min with serum-containing medium and immunoprecipitated as previously described (Blind et al., 1995) Figure 2e) were refractile, oval in shape, and grew in large, round, tight colonies. Saturation density and growth rates were signi®cantly increased (P50.05 vs D/WT) compared to D/WT cells, (Table 1) , and in vitro/in vivo transformation tests (foci formation, growth in soft agar, and induction of tumors in nude mice) revealed that D/N17/e cells exhibited the full neoplastic phenotype. Thus, by reversing the growth arrest induced by ras N17, PKCe appears to act downstream of ras in the induction of cell proliferation and neoplastic transformation in rat colonic epithelial cells.
From the results of the experiments described in this report, we conclude that stable transfection with dominant-negative raf reverts the neoplastic phenotype displayed by D/e cells, and that PKCe can overcome the growth arrest induced by dominantnegative ras in D/WT cells. Moreover, overexpression (Morgenstern and Land, 1990) ; Stably transfected cell lines were obtained as previously described from independent mass-culture transfection experiments which were each repeated three times with identical results of either PKCe or oncogenic ras in rat colonic D/WT cells markedly enhanced the phosphorylation of Raf-1. These ®ndings indicate that PKCe expresses its oncogenic activity in these colonic epithelial cells by interacting with the ras pathway at the level of Raf-1 activation. In particular, it appears that PKCe acts upstream of Raf-1 and downstream of p21ras. These results are congruent with two recent reports, proposing that PKCe may act by coupling p21ras to Raf. Cai et al. (1997) have shown that a truncated regulatory domain of PKCe, acting as a dominantnegative mutant, inhibited both proliferation of NIH3T3 cells and activation of Raf in COS cells. Conversely, overexpression of wild-type PKCe stimulated Raf kinase activity in COS cells and overcame the inhibitory eect of N17 ras in NIH3T3 cells (Cai et al., 1997) . Analogous results were reported by Cacace and coworkers in rat R6 ®broblasts (Cacace et al., 1996) . These authors have shown that PKCe-overproducing cells exhibited a marked increase in Raf-1 kinase and ERK activities, that dominant-negative raf reversed transformation induced by PKCe in R6 cells, that these reverted clones exhibited decreased Raf activity, and that dominant-negative ras did not reverse the PKCeinduced transformed phenotype.
With respect to colon carcinogenesis, as modeled in rat colonic epithelial cells, we propose that overexpressed PKCe acts as an oncogene by providing a sustained stimulatory signal to Raf-1, bypassing the ®ne regulatory circuitry normally controlled by growth factors, growth factor receptors, adaptor molecules, GTPase-activating proteins, and other elements (Malarkey et al., 1995) .
Based on our ®ndings, and on those of others Cacace et al., 1993 Cacace et al., , 1996 Cai et al., 1993 Cai et al., , 1997 , the role of PKCe as a novel oncogene in a variety of cell models is becoming more evident.
